Education
About Us
Working with TipRanks
Follow Us
Imunon (IMNN)
NASDAQ:IMNN
Earnings Data
Report Date
May 19, 2025TBA Not Confirmed
Period Ending
2025 (Q1)Consensus EPS Forecast
-0.35Last Year’s EPS
-0.52Same Quarter Last Year
Moderate Buy
Based on 1 Analysts Ratings
---
Earnings Call Summary
Earnings Call Date:Feb 27, 2025
|% Change Since: 12.50%
|Next Earnings Date:May 19, 2025
Earnings Call Sentiment|Positive
The earnings call highlighted significant progress in clinical trials and potential for accelerated approval of Imunon-001, alongside strong safety data. However, concerns about cash runway and funding needs were also discussed, indicating a need for careful financial management.Company Guidance
In the recent conference call, Imunon, Inc. provided guidance on several key metrics related to their progress and future plans. They highlighted the success of their Phase 2 OVATION 2 study for Imunon-001 in treating advanced ovarian cancer, showing a median overall survival improvement from 11 months to 13 months over standard care. This compelling data has led to FDA agreement to initiate a pivotal Phase 3 study, with treatment expected to start in March 2025. The company is focused on an aggressive timeline for commercialization, supported by promising translational data and a favorable benefit-risk profile. Imunon-001 showed a strong dose response in IL-12 levels, maintaining low systemic levels to avoid toxicity. Financially, Imunon, Inc. reported a net loss of $18.6 million for 2024 with a cash runway extending into the second quarter of 2025 and is actively seeking financing and partnerships to support its strategic objectives.Positive Results from OVATION 2 Study
Imunon, Inc. announced positive results from the Phase 2 OVATION 2 study, showing an improvement in median overall survival of 13 months compared to the standard of care in ovarian cancer patients.
Phase 3 Study Initiation
The company is on track to initiate the pivotal Phase 3 OVATION 3 study in March 2025, following supportive feedback from the FDA.
Translational Data from OVATION 2
New translational data indicates a strong dose response in IL-12 levels, with 100 mg/m^2 showing about a 20% increase compared to the previous highest dose studied, demonstrating the potential for effective treatment with a favorable safety profile.
Potential for Accelerated Approval
The company is optimistic about the potential for accelerated approval based on the strength of OVATION 2 data, particularly in subgroups such as women receiving PARP inhibitors.
Strong Safety Profile
Imunon-001 demonstrates a favorable benefit-risk profile, with no elevation of immune-related adverse events or cytokine release syndrome observed.
---
IMNN Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
---
IMNN Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
| Feb 27, 2025 | $0.80 | $0.81 | +1.25% |
| Nov 07, 2024 | $0.94 | $0.82 | -12.77% |
| Aug 14, 2024 | $1.08 | $0.96 | -11.11% |
| May 13, 2024 | $1.38 | $1.48 | +7.25% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
---
FAQ
When does Imunon (IMNN) report earnings?
Imunon (IMNN) is schdueled to report earning on May 19, 2025, TBA Not Confirmed.
What is Imunon (IMNN) earnings time?
Imunon (IMNN) earnings time is at May 19, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is IMNN EPS forecast?
IMNN EPS forecast for the fiscal quarter 2025 (Q1) is -0.35.
---